This section provides general information on HCW and key elements of management procedures that are essential to know before developing a HCWM plan.
Prices people pay for medicines.
Health Policy Plan (2017) 32 (5): 603-612; 10 pp. 318 kB
РУКОВОДСТВО ПО БИОЛОГИЧЕСКОЙ БЕЗОПАСНОСТИ ЛАБОРАТОРНЫХ ИССЛЕДОВАНИЙ ПРИ ТУБЕРКУЛЕЗЕ.
Examination of the business behavior of Boehringer Ingelheim, Bayer and Baxter in India
Clinical Infectious Diseases
1586 - 1594 • CID 2016:62 (15 June) • HIV/AIDS
Integrating the prevention and control of noncommunicable diseases in HIV/AIDS, tuberculosis, and sexual and reproductive health programmes: implementation guidance
This report provides a review and analysis of the research landscape for three diseases – Chagas disease, human African trypanosomiasis and leishmaniasis – that disproportionately afflict poor and remote populations with limited access to health services. It represents the work of the disease re...ference group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis (DRG3) which was established to identify key research priorities through review of research evidence and input from stakeholders' consultations.
more
A review of prospects for existing antibiotics ad new therapeutics
To understand the patterns of Rwanda’s achievements in health development, it is important to explore how Rwanda addresses the Social Determinants of Health (SDH) particularly those related to routine conditions in which people are born, live and work. It is in this particular context that a case ...study on Rwanda’s Performance in Addressing Social Determinants of Health was conducted by the Rwanda Ministry of Health, with technical and financial support from the World Health Organization (WHO). The overall goal of the exercise was to document Rwanda's recent initiatives that contribute to the advancements of the Rio Political Declaration on Social Determinants of Health.
more